JP2023534720A5 - - Google Patents

Info

Publication number
JP2023534720A5
JP2023534720A5 JP2023504330A JP2023504330A JP2023534720A5 JP 2023534720 A5 JP2023534720 A5 JP 2023534720A5 JP 2023504330 A JP2023504330 A JP 2023504330A JP 2023504330 A JP2023504330 A JP 2023504330A JP 2023534720 A5 JP2023534720 A5 JP 2023534720A5
Authority
JP
Japan
Prior art keywords
intron
antisense oligonucleotide
sequence
seq
target region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534720A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2021/050788 external-priority patent/WO2022016222A1/en
Publication of JP2023534720A publication Critical patent/JP2023534720A/ja
Publication of JP2023534720A5 publication Critical patent/JP2023534720A5/ja
Pending legal-status Critical Current

Links

JP2023504330A 2020-07-22 2021-07-22 Scn2a中の機能喪失変異に関連する障害を処置するための組成物及び方法 Pending JP2023534720A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902550 2020-07-22
AU2020902550A AU2020902550A0 (en) 2020-07-22 Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A
PCT/AU2021/050788 WO2022016222A1 (en) 2020-07-22 2021-07-22 Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a

Publications (2)

Publication Number Publication Date
JP2023534720A JP2023534720A (ja) 2023-08-10
JP2023534720A5 true JP2023534720A5 (cg-RX-API-DMAC10.html) 2024-07-18

Family

ID=79729542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504330A Pending JP2023534720A (ja) 2020-07-22 2021-07-22 Scn2a中の機能喪失変異に関連する障害を処置するための組成物及び方法

Country Status (15)

Country Link
US (1) US20230272387A1 (cg-RX-API-DMAC10.html)
EP (1) EP4185697A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023534720A (cg-RX-API-DMAC10.html)
KR (1) KR20230095056A (cg-RX-API-DMAC10.html)
CN (1) CN116368227A (cg-RX-API-DMAC10.html)
AU (1) AU2021311137A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023000988A2 (cg-RX-API-DMAC10.html)
CA (1) CA3186629A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023000208A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023001922A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP23012641A (cg-RX-API-DMAC10.html)
IL (1) IL299999A (cg-RX-API-DMAC10.html)
MX (1) MX2023000907A (cg-RX-API-DMAC10.html)
PE (1) PE20230982A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022016222A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250146073A1 (en) * 2022-02-04 2025-05-08 Praxis Precision Medicines, Inc. Methods for the treatment of scn2a-related disorders
KR20250180156A (ko) 2024-06-21 2025-12-31 중앙대학교 산학협력단 뇌전증의 예방 또는 치료용 조성물, 및 뇌전증 치료제 스크리닝 방법과 이의 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1846501A (en) * 1999-11-26 2001-06-04 Bionomics Limited Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
AU2001250572A1 (en) * 2000-04-07 2001-10-23 Epigenomics Ag Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
WO2002006294A2 (en) * 2000-07-13 2002-01-24 Genaissance Pharmaceuticals, Inc. Haplotypes of the mmp13 gene
WO2005035784A1 (en) * 2003-10-13 2005-04-21 Bionomics Limited A diagnostic method for neonatal or infantile epilepsy syndromes
CN101148665A (zh) * 2005-12-05 2008-03-26 广州医学院第二附属医院 钠离子通道scn1a基因突变及基因突变检测方法和用途
ES2618894T3 (es) * 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
US9364495B2 (en) * 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
WO2013173637A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
GB201410693D0 (en) * 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
EP3481857B1 (en) * 2016-07-06 2026-02-11 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
KR20190030833A (ko) * 2017-09-15 2019-03-25 가톨릭대학교 산학협력단 신장암 환자의 예후 진단 및 치료 전략 결정용 연령 특이적 마커
LT3700570T (lt) * 2017-10-23 2025-04-10 Stoke Therapeutics, Inc. Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui
WO2019143831A1 (en) * 2018-01-17 2019-07-25 Rogcon U.R., Inc. Compositions and methods for increasing expression of scn2a
CA3110211A1 (en) * 2018-08-20 2020-02-27 Rogcon, Inc. Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies
US20220090087A1 (en) * 2019-01-23 2022-03-24 The Florey Institute Of Neuroscience And Mental Health Antisense oligonucleotides targeting scn2a retained introns

Similar Documents

Publication Publication Date Title
Morihiro et al. Biological applications of xeno nucleic acids
JP7478923B2 (ja) シュードウリジン化のための核酸分子
WO2020198509A2 (en) Modified oligonucleotides with increased stability
JP6813506B2 (ja) レーバー先天性黒内障のためのオリゴヌクレオチド療法
JP2021533804A5 (cg-RX-API-DMAC10.html)
TW201726918A (zh) 抑制lpa之基因表現之組合物及方法
EP3234134A1 (en) Targeted rna editing
CN105008533A (zh) 嵌合单链反义多核苷酸和双链反义试剂
CA3118167A1 (en) Bispecific antisense oligonucleotides for dystrophin exon skipping
WO2022217366A1 (en) Modified oligonucleotides for the treatment of duchenne muscular dystrophy
BR112020010090A2 (pt) oligonucleotídeo gapmer, sal farmaceuticamente aceitável do mesmo, conjugado, composição farmacêutica e uso dos mesmos
JP2023518268A5 (cg-RX-API-DMAC10.html)
JP2024543000A (ja) 操作されたrna
KR20250125967A (ko) 진보된 rna 표적화 (arnatar)
US20250313832A1 (en) Compositions for treating syngap-1 related neurodevelopmental disorders
JP2024522272A5 (cg-RX-API-DMAC10.html)
JP2024542738A5 (cg-RX-API-DMAC10.html)
JP2023534720A (ja) Scn2a中の機能喪失変異に関連する障害を処置するための組成物及び方法
TW202309286A (zh) 作為新穎基因靜默技術的非對稱短雙股dna及其應用
JP2024520555A5 (cg-RX-API-DMAC10.html)
JPWO2019004420A1 (ja) ヘテロ二本鎖型antimiR
CA3173399A1 (en) Bifunctional molecules and methods of using thereof
WO2020171149A1 (ja) ヘテロ核酸の最適ps修飾パターン
BR112020012427A2 (pt) oligonucleotídeo, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, processo para a fabricação de um oligonucleotídeo, oligonucleotídeo fabricado e invenção
CN121127248A (zh) 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法